- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
The Market’s Top 10 Stocks in 2014 презентация
Содержание
- 1. The Market’s Top 10 Stocks in 2014
- 2. #10 - Skyworks Solutions: +156.4% What it
- 3. #9 - Chimerix: +166.4% What it does:
- 4. #8 - Hawaiian Holdings: +170.5% What it
- 5. #7 - Tetraphase Pharmaceuticals: +193.7% What it
- 6. #6 - PTC Therapeutics: +205.1% What it
- 7. #5 - Achillion Pharmaceuticals: +269.1% What it
- 8. #4 - Receptos: +322.6% What it does:
- 9. #3 - bluebird bio: +337.2% What it
- 10. #2 - Agios Pharmaceuticals: +367.8% What it
- 11. #1 - Avanir Pharmaceuticals: +404.5% What it
- 12. 1 Great Healthcare Stock to Buy for
#10 - Skyworks Solutions: +156.4% What it does:
Produces connectivity-related chips for tech devices. Why it soared:
New iPhone product lines and other mobile devices boosted sales, as well
Слайд 2#10 - Skyworks Solutions: +156.4%
What it does:
Produces connectivity-related chips for
tech devices.
Why it soared: New iPhone product lines and other mobile devices boosted sales, as well as optimism about the Internet of Things.
Why it soared: New iPhone product lines and other mobile devices boosted sales, as well as optimism about the Internet of Things.
Слайд 3#9 - Chimerix: +166.4%
What it does:
Maker of anti-viral compounds to
treat viral diseases.
Why it soared: Accelerated trials for its brincidofovir treatment for bone-marrow transplant recipients could bring faster approval.
Why it soared: Accelerated trials for its brincidofovir treatment for bone-marrow transplant recipients could bring faster approval.
Слайд 4#8 - Hawaiian Holdings: +170.5%
What it does:
Airline connecting passengers from
Asia and the U.S. mainland to Hawaii, and inter-island travel within Hawaii.
Why it soared: Strong competitive position in Hawaii, plus plunging fuel costs and strong economic conditions in 2014.
Why it soared: Strong competitive position in Hawaii, plus plunging fuel costs and strong economic conditions in 2014.
Слайд 5#7 - Tetraphase Pharmaceuticals: +193.7%
What it does:
Maker of antibiotic treatments
for intra-abdominal and other infections.
Why it soared: Fast-track designation for lead drug candidate eravacycline could speed FDA approval.
Why it soared: Fast-track designation for lead drug candidate eravacycline could speed FDA approval.
Слайд 6#6 - PTC Therapeutics: +205.1%
What it does:
Produces small-molecule drugs to
treat genetic mutations.
Why it soared: Positive opinion and trials for its lead compound translarna to treat a form of muscular dystrophy.
Why it soared: Positive opinion and trials for its lead compound translarna to treat a form of muscular dystrophy.
Слайд 7#5 - Achillion Pharmaceuticals: +269.1%
What it does:
Makes therapies to treat
hepatitis C and other bacterial infections.
Why it soared: Favorable prospects for its ACH-3102 hepatitis C combination treatment spurred optimism.
Why it soared: Favorable prospects for its ACH-3102 hepatitis C combination treatment spurred optimism.
Слайд 8#4 - Receptos: +322.6%
What it does:
Develops therapies to treat immune
disorders.
Why it soared: Promising trial results on its RPC1063 multiple sclerosis drug could bring eventual approval.
Why it soared: Promising trial results on its RPC1063 multiple sclerosis drug could bring eventual approval.
Слайд 9#3 - bluebird bio: +337.2%
What it does:
Maker of gene-based therapies
to treat genetic disorders.
Why it soared: Encouraging trial results for a key treatment of orphan-disease genetic disorders suggested huge potential success for the company.
Why it soared: Encouraging trial results for a key treatment of orphan-disease genetic disorders suggested huge potential success for the company.
Слайд 10#2 - Agios Pharmaceuticals: +367.8%
What it does:
Makes metabolism-focused treatments to
fight cancer and other diseases.
Why it soared: Agios’ partner Celgene exercised its option to market potential cancer-fighter AG-221 following positive trial results.
Why it soared: Agios’ partner Celgene exercised its option to market potential cancer-fighter AG-221 following positive trial results.
Слайд 11#1 - Avanir Pharmaceuticals: +404.5%
What it does:
Maker of treatments for
central nervous system disorders, including Nuedexta treatment for pseudobulbar affect.
Why it soared: Agreed to $3.5 billion purchase offer from Japan’s Otsuka Pharmaceuticals.
Why it soared: Agreed to $3.5 billion purchase offer from Japan’s Otsuka Pharmaceuticals.
Слайд 121 Great Healthcare Stock to Buy for 2015 and Beyond
Healthcare stocks
soared in 2014, and 2015 is shaping up to be another great year for stocks. But if you want to make sure you're buying one of the best healthcare stocks, you need to know where to start. That's why The Motley Fool's chief investment officer just published a brand-new research report that reveals his top stock for the year ahead. To get the full story on this year's stock -- completely free - just click below.
